MannKind Corporation and One drop have announced a partnership for a study of the Afrezza inhaled Insulin and One Drop’s diabetes platform.
The hope is to discover a new and simpler way to take insulin.
Dr. Raymond Urbanski, Chief Medical Officer of MannKind Corporation, said, “This study is intended to evaluate whether combining a solutions-oriented digital disease management platform like One Drop with an innovative drug like Afrezza® will provide patients with an improved ability to manage their diabetes.”
Click here to read the full release.
(Credit: One Drop)
